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Clinics and pathology 
Disease 
Treatment related acute myeloid leukaemia (t-AML). 
Epidemiology 






Genes involved and Proteins 





Transcrition factor; EVI1 targets include:GATA2, 
ZBTB16 /PLZF, ZFPM2/FOG2, JNK and the 
PI3K/AKT pathway. Role in cell cycle progression, 
likely to be cell-type dependant; antiapoptotic factor; 
involved in neuronal development organogenesis; role 
in hematopoietic differsntiation. 
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